Floatz logo

Ezetimibe

Peripheral Arterial Disease

University of OxfordSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Peripheral Arterial Disease cohort.

Asset / SponsorPhaseRating
CLOPIDOGREL
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BBB
Aspirin
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BBB
Cilostazol
University of Ioannina
Phase 4BB
Ranolazine
Colorado Prevention Center
Phase 4BB
Ticagrelor
AstraZeneca
Phase 3BB

View all 14 →

Same molecule, other indications

Ezetimibe is also rated in:

coronary artery disorderDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
inherited lipid metabolism disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →
hyperlipidemiaActive
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →